ETF Securities launches CURE ETF


ETF Securities has launched its new CURE exchange-traded fund (ETF) on the Australian Securities Exchange (ASX), which will offer investors exposure to healthcare biotechnology companies.
CURE would follow the S&P Biotechnology Select Industry Index, which according to the company, achieved annual growth of 21.9 per cent in Australian dollar terms over the five years to 31 October 2018.
Additionally, the fund would hold more than 120 biotechnology firms in its portfolio, with a focus on small and mid-cap companies. The fund’s fee would stand at 0.45 per cent.
Head of ETF Securities Australia, Kris Walesby, said: “This is very much a high growth-oriented product.”
“Given the mainly mid- and small-cap profiles of the constituent stocks, we’d expect to see profitable M&A activity. We are pleased to be adding CURE to our ‘Future Present’ series of ETFs.”
Walesby also stressed that there would be demanding filters to be met before a company can be included in CURE, with companies needing to meet S&P Dow Jones Indices’ Float Adjustment liquidity requirements.
Recommended for you
The $673 billion global investment manager has appointed a former Zenith sales head as it seeks to expand its reach in the Australian wealth management market.
Fund managers may be operating in a squeezed environment, but a salary guide shows they are willing to pay up for specialist talent to diversify their fund range.
Reach Alternative Investments has entered into a strategic partnership with Russell Investments to bolster its wholesale private markets offering for financial advisers and investors.
Boutique investment consulting and research house Genium Investment Partners has announced a senior appointment to drive further growth in its research ratings business.